ITGAV/ITGB6 antibody (FITC)
Quick Overview for ITGAV/ITGB6 antibody (FITC) (ABIN714813)
Target
Reactivity
Host
Clonality
Conjugate
Application
-
-
Cross-Reactivity
- Human, Mouse, Rat
-
Purification
- Purified by Protein A.
-
Immunogen
- KLH conjugated synthetic peptide derived from human Integrin Alpha V + Beta 6
-
Isotype
- IgG
-
-
-
-
Application Notes
-
FCM 1:20-100
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200 -
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- 1 μg/μL
-
Buffer
- Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.
-
Preservative
- ProClin
-
Precaution of Use
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
-
Storage
- -20 °C
-
Storage Comment
- Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
-
Expiry Date
- 12 months
-
-
- ITGAV/ITGB6 (Integrin alpha V, Integrin beta 6 (ITGAV/ITGB6))
-
Alternative Name
- Integrin Alpha V + Beta 6
-
Background
-
Synonyms: CD51, Integrin alpha-V light chain, integrin, alpha V vitronectin receptor, alpha polypeptide, antigen CD51, Integrin, alpha V, Integrin, beta 6, ITAV_HUMAN, ITGAV, ITGB6, Vitronectin receptor subunit alpha.
Background: Integrins are heterodimeric cell surface receptors composed of alpha and beta subunits, which mediate cell-cell and cell-extracellular matrix attachments. Aberrant integrin expression has been found in many epithelial tumours. Changes in integrin expression have been shown to be important for the growth and early metastatic capacity of melanoma cells. Integrin alpha-v beta-6 is upregulated in cancers and during tissue remodelling but is absent from resting adult tissues. Integrin alpha-v beta-6 promotes invasion and correlates with poor survival and therefore makes a promising therapeutic target.
-
Gene ID
- 36853694
Target
-